Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study

Ruth D Simmons, Peter Kirwan, Kazim Beebeejaun, Andrew Riordan, Ray Borrow, Mary E Ramsay, Valerie Delpech, Samuel Lattimore, Shamez Ladhani, Ruth D Simmons, Peter Kirwan, Kazim Beebeejaun, Andrew Riordan, Ray Borrow, Mary E Ramsay, Valerie Delpech, Samuel Lattimore, Shamez Ladhani

Abstract

Background: Recent studies have identified HIV infection as a potential risk factor for invasive meningococcal disease (IMD), suggesting that HIV-infected individuals could benefit from meningococcal vaccination to reduce their risk of this rare, but severe and potentially fatal infection. In the United Kingdom, as in most industrialised countries, HIV is not considered a risk factor for IMD.

Methods: IMD incidence and relative risk by age group and meningococcal capsular group in HIV-positive compared with HIV-uninfected individuals was estimated through data linkage of national datasets in England between 2011 and 2013.

Results: IMD incidence among persons diagnosed with HIV was 6.6 per 100,000 compared to 1.5 per 100,000 among HIV-negative individuals, with a relative risk of 4.5 (95 % CI, 2.7-7.5). All but one case occurred in adults aged 16-64 years, who had a 22.7-fold (95 % CI, 12.4-41.6; P <0.001) increased risk compared with the HIV-negative adults. IMD risk by capsular group varied with age. HIV-positive children and adolescents had a higher risk of meningococcal group B disease, while adults were at increased risk of groups C, W and Y disease. Most HIV-positive individuals had been born in Africa, had acquired HIV through heterosexual contact, and were known to be HIV-positive and receiving antiretroviral treatment at IMD diagnosis. The most common clinical presentation was septicemia and, although intensive care admission was common, none died of IMD.

Conclusions: HIV-positive children and adults are at significantly increased risk of IMD, providing an evidence base for policy makers to consider HIV as a risk factor for meningococcal vaccination.

References

    1. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36. doi: 10.1016/j.vaccine.2011.12.032.
    1. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–9. doi: 10.1016/j.vaccine.2009.04.067.
    1. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710–6. doi: 10.1016/j.vaccine.2012.03.011.
    1. Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–85. doi: 10.1093/cid/ciu881.
    1. Department of Health . Immunisation against infectious disease - the ‘Green Book’ 2006. London: Department of Health; 2008.
    1. British HIV Association, British Association for Sexual Health and HIV, British Infection Society. UK national guidelines for HIV testing 2008. London: British HIV Association; 2008. Available from: .
    1. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med. 1995;123(12):937–40. doi: 10.7326/0003-4819-123-12-199512150-00007.
    1. Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS. 2010;24(9):1351–60. doi: 10.1097/QAD.0b013e32833a2520.
    1. Pinner RW, Onyango F, Perkins BA, Mirza NB, Ngacha DM, Reeves M, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis. 1992;166(2):359–64. doi: 10.1093/infdis/166.2.359.
    1. Gilks CF, Brindle RJ, Otieno LS, Simani PM, Newnham RS, Bhatt SM, et al. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet. 1990;336(8714):545–9. doi: 10.1016/0140-6736(90)92096-Z.
    1. Brindle R, Simani P, Newnham R, Waiyaki P, Gilks C. No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya. Trans R Soc Trop Med Hyg. 1991;85(5):651. doi: 10.1016/0035-9203(91)90380-H.
    1. Kipp W, Kamugisha J, Rehle T. Meningococcal meningitis and HIV infection: results from a case-control study in western Uganda. AIDS. 1992;6(12):1557–8. doi: 10.1097/00002030-199212000-00031.
    1. Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014;160(1):30–7. doi: 10.7326/0003-4819-160-1-201401070-00731.
    1. Unit MR, Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(Pt 7):887–96.
    1. Public Health England. HANDD metadata files. London: Public Health England; 2015. Available from:
    1. Public Health England. SOPHID metadata files. London: Public Health England; 2015. Available from:
    1. Public Health England. CD4 surveillance metadata files. London: Public Health England; 2015. Available from: .
    1. National Health Service. The Health Service (Control of Patient Information) Regulations 2002. No. 1438. London: The Stationery Office; 2002. Available from: .
    1. Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161(4):676–81. e2.
    1. Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445–50. doi: 10.1136/.
    1. Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis. 2012;18(1):63–70. doi: 10.3201/eid1801.110901.
    1. Ozaki B, Kittai A, Chang S. Neisseria meningitidis as a cause of facial cellulitis. BMJ Case Rep. 2014;2014. doi: 10.1136/bcr-2014-203774.
    1. Weiss D, Varma JK. Control of recent community-based outbreaks of invasive meningococcal disease in men who have sex with men in Europe and the United States. Euro Surveill. 2013;18(28).
    1. Simon MS, Weiss D, Gulick RM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159(4):300–1. doi: 10.7326/0003-4819-159-4-201308200-00674.
    1. Marcus U, Vogel U, Schubert A, Claus H, Baetzing-Feigenbaum J, Hellenbrand W, et al. A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to May 2013. Euro Surveill. 2013;18(28).
    1. Schmink S, Watson JT, Coulson GB, Jones RC, Diaz PS, Mayer LW, et al. Molecular epidemiology of Neisseria meningitidis isolates from an outbreak of meningococcal disease among men who have sex with men, Chicago, Illinois, 2003. J Clin Microbiol. 2007;45(11):3768–70. doi: 10.1128/JCM.01190-07.
    1. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease among men who have sex with men. Stockholm: ECDC; 2013. Available from: .
    1. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.
    1. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–7. doi: 10.1128/CVI.00529-09.
    1. Rice BD, Delpech VC, Chadborn TR, Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. Sex Transm Dis. 2011;38(8):685–90.
    1. NHS Choices. Meningitis B jab to be added to NHS child vaccine schedule. London: NHS Choices; 2015. Available from: .
    1. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74. doi: 10.1016/j.vaccine.2013.08.006.
    1. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014;28(7):1049–57. doi: 10.1097/QAD.0000000000000212.
    1. Public Health England. Meningococcal group W (MenW) immunisation advised for 14 to 18 year-olds. London: Public Health England; 2015. Available from: .
    1. Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, et al. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. Pediatr Infect Dis J. 2015;34(5):e113–8. doi: 10.1097/INF.0000000000000630.
    1. Geretti AM, BHIVA Immunization Writing Committee. Brook G, Cameron C, Chadwick D, Heyderman RS, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9(10):795–848. doi: 10.1111/j.1468-1293.2008.00637.x.
    1. Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, et al. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2012;31(1):47–52. doi: 10.1097/INF.0b013e318236c67b.
    1. Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics. 2011;128(6):1213–8.
    1. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease Control Use of serogroup B meningococcal vaccines in persons aged >/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–12.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever